0

Thrombogenicity Testing for Blood-Contacting Medical Devices in an In Vitro Human Blood-Loop PUBLIC ACCESS

[+] Author Affiliations
Matt Cunningham, Sarah Howard, Abby Beltrame, Yan Chen, Mark Smith

American Preclinical Services, Minneapolis, MN

Paper No. DMD2018-6875, pp. V001T01A007; 3 pages
doi:10.1115/DMD2018-6875
From:
  • 2018 Design of Medical Devices Conference
  • 2018 Design of Medical Devices Conference
  • Minneapolis, Minnesota, USA, April 9–12, 2018
  • ISBN: 978-0-7918-4078-8
  • Copyright © 2018 by ASME

abstract

Thrombogenicity testing continues to be a critical requirement for regulatory approval of blood-contacting medical devices and the ISO guidelines have recently been updates [1]. This new guideline ascribes value to both in vivo and in vitro testing including both the non-anticoagulated venous implant (NAVI) model, and the new methods for in vitro testing. One challenge with the animal-blood-based in vitro assays that have been validated and used for submissions is that they still may not accurately translate to clinical safety or predict the risk for thrombogenic potential in humans. We have previously described a model using minimally heparinized ovine blood and are continuing to improve the overall methodology [2,3]. In addition, we have transferred these methods to a human blood assay which therefore has enhanced potential for prediction of clinical risk. As with the ovine model, the key characteristics of a successful in vitro method include fresh blood, low levels of anticoagulation, flow conditions and minimization of air/blood interfaces. This human model integrates freshly harvested human blood containing minimal levels of heparin with variable flow from a unidirectional peristaltic pump and unlike many of the human blood assays, it can accommodate larger devices and higher flow rates than previously described [1,4]. Control materials which were optimized in the ovine model were also used to reproducibly elicit positive and negative thrombogenic responses. We feel that this model can be used for validation of the ovine model with cross comparisons of a number of legally marketed comparator devices. Alternatively, if the human blood methodology can be streamlined and performed cost effectively on a regular and basis, this assay could supplant the current ovine model and allow a highly predictive preclinical test for thrombogenicity of devices.

Copyright © 2018 by ASME
This article is only available in the PDF format.

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging and repositioning the boxes below.

Related eBook Content
Topic Collections

Sorry! You do not have access to this content. For assistance or to subscribe, please contact us:

  • TELEPHONE: 1-800-843-2763 (Toll-free in the USA)
  • EMAIL: asmedigitalcollection@asme.org
Sign In